Merck and Its Employees to Donate to Japanese Relief Effort

Merck KGaAMerck KGaA announced that in order to provide assistance to the Japanese people following the earthquake and tsunami that devastated parts of their country, the company will donate a total of 100 million YEN (approximately EUR 875,000). The major part of the donation will be given to the international relief organization "Save the Children". Merck's Japanese subsidiaries will decide how the remainder of the donation will be distributed. The region around Onahama, where one of Merck's production sites is located and which is close to the Fukushima nuclear power plant, will definitely benefit from the donations.

The company is also encouraging its employees to make donations and has agreed to match employee contributions. These funds will also be given to "Save the Children".

Dr. Karl-Ludwig Kley, Chairman of the Executive Board of Merck, said: "Our thoughts are with all the people in the regions impacted by the tragedy. We sincerely hope that the situation in Fukushima will be controlled soon and that no additional damage will occur so that reconstruction can start soon. Our donations are meant to help and support Japan."

Kley added: "During the years I lived in Japan, I had the opportunity to experience and understand the strength, courage and dedication of the Japanese people. I therefore firmly believe that this country will emerge stronger from this national tragedy. Merck will support Japan in that effort by continuing to invest there in research and development and operations."

The Merck Executive Board also has decided to set up an aid fund to support its Japanese employees whose property was damaged or destroyed by the natural disasters. Merck has approximately 1,000 employees in Japan.

Merck is a global pharmaceutical and chemical company with total revenues of EUR 9.3 billion in 2010, a history that began in 1668, and a future shaped by more than 40,000 employees in 67 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...